Generics and biosimilars in Italy

Nowadays, generic and biosimilar drugs are considered the key for cutting pharmaceutical expenditure. Apart from the saving expenses aspect, generics and biosimilars are different kind of products. In fact, generics are duplicates of brand-name drugs which do not have a registered trademark. Biosimilars, on the other hand, are drugs of biological origin which are very similar in function and effect to previously approved biological products. After providing a global overview of the market of generics and biosimilars, this report offers some insights about the Italian market and a global outlook.